Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No Big Surprises From Lilly: Management Sticks To Its Guns On Strategy

This article was originally published in The Pink Sheet Daily

Executive Summary

With the loss of Zyprexa just months away, Eli Lilly management sought to reassure investors its strategy of focusing on its internal pipeline and core growth areas will pay off post-2014.
Advertisement

Related Content

Lilly BioMedicines Head Ricks Tasked With Overseeing Growth Phase As Next CEO
Lilly’s Intended Successor To Zyprexa Faces Uncertain Future After Phase III Failure
Lilly Prepares For Zyprexa Expiration; Increases R&D Spend
Aura Biosciences Prepares To Move Nano-Enabled Drug Delivery System Into The Clinic
Pipeline Of Alzheimer's Drugs Targeting Amyloid-Beta Protein
Boehringer/Lilly To Price Tradjenta On Par With Rival DPP-4 Inhibitors
Boehringer/Lilly To Price Tradjenta On Par With Rival DPP-4 Inhibitors
Blood Clot Risk Causes Lilly, Bristol To Halt Enrollment In Erbitux Follow-On Trial
Bydureon Goes Back To The QTc Drawing Board
Lilly To Cease Development of Phase III Alzheimer's Drug

Topics

Advertisement
UsernamePublicRestriction

Register

PS072458

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel